Childrens Research Inst — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$70,406	4
2021	Research	$218,099	101
2020	Research	$57,052	4
2019	Research	$37,580	42

Breakdown

Who paid Research payments · program years 2019–2023

Bioverativ Therapeutics Inc. $249,679 142 payments
Amgen Inc. $111,695 7 payments
AstraZeneca Pharmaceuticals LP $21,763 2 payments

Studies the money was for Research payments · program years 2019–2023

An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A $218,099 101 payments
Ph3 Pediatric CM Study $56,338 2 payments
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously $25,665 29 payments
Ph3 Pediatric CM Study. $25,269 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $21,763 2 payments
Phase P3 Pediatric Study (EM) $14,068 2 payments
Phase P3 Pediatric Study (EM). $10,020 1 payment
4020 - CFZ Ph1 Pediatric ALL (CFZ 008) $6,000 1 payment
An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A $4,823 6 payments
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untr $1,092 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.